Concomitant systemic mastocytosis (SM) can complicate acute myeloid leukaemia (AML) with t(8;21) and its recognition, particularly in the presence of KIT D816 mutations, according ...

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

Tatiana Schlossberg, the youngest granddaughter of President John F. Kennedy, recently revealed she was diagnosed with terminal acute myeloid leukemia (AML) due to a rare genetic anomaly. In a ...

As evidence continues to evolve, optimising sequencing, duration, MRD-guided use, and combination approaches will be important areas of focus to improve patient outcomes ...

A case of acute myeloid leukemia with mast cell differentiation (AML-MC) that subsequently fulfilled diagnostic criteria for mast cell leukemia (MCL), an aggressive type of systemic mastocytosis (SM), ...

Disruptions in transcriptional regulation during hematopoiesis can lead to abnormal hematopoietic differentiation and the development of leukemia. Understanding the underlying mechanisms of disease ...

Molecular lesion data in LR-MDS prognostic models reduce the significance of traditional parameters like bone marrow blast percentage. Molecular data altered risk stratification for 30% of patients, ...

Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called proteasome inhibitors, which work well in multiple myeloma. A new study by ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...